CA
TEVA icon

Clearstead Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Clearstead Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.7K Buy
2,765
+2,748
+16,165% +$91.5K ﹤0.01% 1311
2026
Q1 		$513 Hold
17
– – ﹤0.01% 2118
2025
Q4 		$531 Hold
17
– – ﹤0.01% 2303
2025
Q3 		$344 Sell
17
-808
-98% -$14.2K ﹤0.01% 2787
2025
Q2 		$13.8K Hold
825
– – ﹤0.01% 1771
2025
Q1 		$12.7K Buy
825
+808
+4,753% +$14.4K ﹤0.01% 1552
2024
Q4 		$375 Hold
17
– – ﹤0.01% 2000
2024
Q3 		$307 Hold
17
– – ﹤0.01% 1982
2024
Q2 		$277 Buy
+17
New +$262 ﹤0.01% 1968
2021
Q1 		– Sell
-75
Closed -$1K – 1178
2020
Q4 		$1K Hold
75
– – ﹤0.01% 957
2020
Q3 		$1K Hold
75
– – ﹤0.01% 862
2020
Q2 		$1K Hold
75
– – ﹤0.01% 771
2020
Q1 		$1K Buy
+75
New +$768 ﹤0.01% 760
2017
Q3 		– Sell
-9,461
Closed -$314K – 256
2017
Q2 		$314K Buy
9,461
+7
+0.1% +$217 0.05% 177
2017
Q1 		$303K Buy
9,454
+1,926
+26% +$65.7K 0.04% 176
2016
Q4 		$273K Buy
+7,528
New +$301K 0.04% 175

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Clearstead Advisors's TEVA Position: Q2 2026 in Review

Clearstead Advisors increased its Teva Pharmaceuticals (TEVA) stake by 16,165% in Q2 2026, buying an estimated $91.5K and bringing the position to 2,765 shares worth $93.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Clearstead Advisors first reported a position in TEVA in Q4 2016 and has held it in 16 quarters since. The position peaked at $314K in Q2 2017. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Clearstead Advisors held 2,765 shares of Teva Pharmaceuticals worth $93.7K as of Q2 2026.
  • Clearstead Advisors bought 2,748 Teva Pharmaceuticals shares in Q2 2026, an estimated $91.5K.
  • Teva Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1311 holding.
  • Clearstead Advisors first reported a position in Teva Pharmaceuticals in Q4 2016 and has held it in 16 quarters since.
  • Clearstead Advisors's Teva Pharmaceuticals position peaked at $314K in Q2 2017.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.